Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study

Deesje Doppenberg, Thomas F. Stoop, Susan van Dieren, Matthew H. G. Katz, Quisette P. Janssen, Naaz Nasar, Laura R. Prakash, Rutger T. Theijse, Ching‐Wei D. Tzeng, Alice C. Wei, Amer H. Zureikat, Bas Groot Koerkamp, Marc G. Besselink